ArticleClinical drug investigation2023

A Cost-effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China.

Yanqing Jiang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.